



IBA to install Egypt's first proton therapy center

Contract signed with Children's Cancer Hospital Foundation Egypt to install a Proteus[®]ONE solution in Cairo

Louvain-La-Neuve, Belgium, 28 April 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract with the Children's Cancer Hospital Foundation Egypt (CCHF), a leading NGO in Egypt, to install a Proteus[®]ONE* compact proton therapy solution at Hospital 57357 (CCHE) in Cairo.

This contract covers the delivery of a Proteus[®]ONE solution, including the latest generation Pencil Beam Scanning, isocenter volumetric imaging (Cone Beam CT) capabilities and a long-term maintenance agreement. The hospital plans to start treating patients by 2020. The typical end-user price for a Proteus[®]ONE system with a maintenance contract is between EUR 35 and 40 million. This will be IBA's 19th installation of the compact single-room proton therapy solution.

Olivier Legrain, Chief Executive Officer of IBA, commented: "Due to the precise nature of its delivery, proton therapy is particularly appropriate for the treatment of children. Children with tumors in the brain, head, neck, spinal cord, lungs, etc., can benefit from this treatment because protons deposit the majority of their energy within a controlled zone while limiting the impact on healthy tissue that surrounds the tumor. The Children's Cancer Hospital Foundation Egypt and Hospital 57357's philosophy and ambition of providing children with cancer access to the most advanced radiation therapy technology is creditable; we're pleased to partner with CCHF and CCHE and to be installing the first proton therapy solution in Egypt."

Prof Sherif Abouelnaga, Chief Executive Officer of Children's Cancer Hospital Egypt 57357, commented: "Our mission is to provide the best comprehensive family-centered quality care and a chance to cure all children with cancer, free of charge and without discrimination. We are excited to partner with IBA to bring the world's leading proton beam therapy equipment to cancer patients in Egypt for the first time. Our vision and ambition is to become the center of excellence in radiotherapy for Africa and the Middle East."

ENDS

About Proteus[®]ONE

Proteus[®]ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus[®]ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide.

* Proteus[®]ONE is the brand name of Proteus[®]235



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Children's Cancer Hospital Egypt 57357

The Children's Cancer Hospital Egypt 57357 (CCHE) widely known as "Hospital 57357" is the largest pediatric oncology hospital in the world with a present capacity of 320 beds. The CCHE is a unique humanitarian project as it was built and is being sustained by donations. In operation since July, 2007, it has quickly become recognized as a leader not only on the national level but also globally; specially in the MENA Region and Africa. The Hospital is providing a new level of world quality healthcare where all children are treated free of charge without discrimination. Utilizing multi-sector cooperation, CCHE is a model of a sustainable healthcare system in the developing world that can be duplicated elsewhere.

The hospital is treating an estimated 45% of Egypt's pediatric cancer cases (number of cases annually) and improving cure rates from less than 20-40% to almost 75%. CCHE's aim is to be able to accept 80 to 90% of annual new cases in Egypt while remaining committed to referrals from Africa and other Arab countries. To achieve this, we have embarked on an important capacity and program expansion project by transitioning from a Hospital to a Health Sciences Campus. Besides doubling its capacity, the new campus includes a Healthcare Sciences Academy to train a new generation of healthcare professionals capable of being change agents in their communities and the latest, a larger out-patient facility to house a cutting edge technology in radiation therapy, the proton therapy, and an advanced research center

After 10 years of operations, the 57357 institution has set a new era of healthcare in Egypt as well as new standards for charity. It has demonstrated internally and to the outside world its potential as a national pride project, a vessel for change, a holder of true medicine and technology and a financially sound and reliable endeavor.

More information can be found at: www.57357.org

Press Release

Regulated information



For further information, please contact:

IBA

Jean-Marc Bothy
Chief Strategy Officer

Soumya Chandramouli

Chief Financial Officer

Bernard Dandoy

Investor Relations

+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan

+44 (0) 20 3709 5700

IBA@consilium-comms.com

Press release | April 28, 2017

IBA | Ion Beam Applications SA

Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Nivelles | VAT : 0428.750.985
T +32 10 47 58 11 | F +32 10 47 58 10 | info@iba-group.com | iba-worldwide.com